用于腺瘤和结肠癌早期检测的血浆蛋白质与糖组学标志物
研究通过高密度抗体微阵列从采血后3年内确诊结肠癌者的血浆中发现差异蛋白,并在腺瘤和癌症样本中验证。BAG4、IL6ST、VWF、EGFR和CD44蛋白/糖组学组合在较大样本集中检测早期结肠癌的曲线下面积范围为0.90(95%CI 0.82至0.98)至0.86(95%CI 0.83至0.88),作者认为应在更大规模研究中进一步检验。
要点
- 在癌前诊断样本中发现78个显著升高的蛋白,其中32个在诊断样本中得到确认。
- 由BAG4、IL6ST、VWF和CD44或EGFR组成的最佳4标志物组合在独立样本集中显示升高。
- 包含EGFR和CD44唾液酸化Lewis-A和Lewis-X内容的蛋白/糖蛋白组合在结肠癌样本中曲线下面积范围为0.90至0.86。
核心结论
- 包含BAG4、IL6ST、VWF、EGFR和CD44蛋白/糖组学的组合在检测早期结肠癌方面表现良好,应在更大规模研究中进一步检验。
研究设计与样本
- 研究创建高密度抗体微阵列,检测采血后3年内确诊结肠癌者(即癌前诊断)与无癌匹配对照之间血浆蛋白水平的差异。
- 潜在标志物在腺瘤或癌症确诊者的血浆样本中与对照进行比较测试。
- 最佳5标志物组合的组分通过免疫印迹在第三套样本集中测试,通过Luminex检测在大型第四套样本集中测试,并在组织微阵列上进行免疫组化(IHC)检测。
主要发现
- 在癌前诊断样本中,发现78个显著(t检验)升高的蛋白,其中32个在诊断样本中得到确认。
- 从这32个蛋白中,建立了由BAG4、IL6ST、VWF和CD44或EGFR组成的最佳4标志物组合。
- 每个组合成员及组合本身在独立的第三和第四套样本集中分别通过免疫印迹和Luminex检测,在诊断腺瘤和癌症样本中显示升高。
- IHC结果显示BAG4、IL6ST和CD44在腺瘤和癌症组织中水平升高。
- 纳入EGFR和CD44唾液酸化Lewis-A和Lewis-X含量提高了组合性能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To discover and confirm blood-based colon cancer early-detection markers. DESIGN: We created a high-density antibody microarray to detect differences in protein levels in plasma from individuals diagnosed with colon cancer <3 years after blood was drawn (ie, prediagnostic) and cancer-free, matched controls. Potential markers were tested on plasma samples from people diagnosed with adenoma or cancer, compared with controls. Components of an optimal 5-marker panel were tested via immunoblotting using a third sample set, Luminex assay in a large fourth sample set and immunohistochemistry (IHC) on tissue microarrays. RESULTS: In the prediagnostic samples, we found 78 significantly (t-test) increased proteins, 32 of which were confirmed in the diagnostic samples. From these 32, optimal 4-marker panels of BAG family molecular chaperone regulator 4 (BAG4), interleukin-6 receptor subunit beta (IL6ST), von Willebrand factor (VWF) and CD44 or epidermal growth factor receptor (EGFR) were established. Each panel member and the panels also showed increases in the diagnostic adenoma and cancer samples in independent third and fourth sample sets via immunoblot and Luminex, respectively. IHC results showed increased levels of BAG4, IL6ST and CD44 in adenoma and cancer tissues. Inclusion of EGFR and CD44 sialyl Lewis-A and Lewis-X content increased the panel performance. The protein/glycoprotein panel was statistically significantly higher in colon cancer samples, characterised by a range of area under the curves from 0.90 (95% CI 0.82 to 0.98) to 0.86 (95% CI 0.83 to 0.88), for the larger second and fourth sets, respectively. CONCLUSIONS: A panel including BAG4, IL6ST, VWF, EGFR and CD44 protein/glycomics performed well for detection of early stages of colon cancer and should be further examined in larger studies.
引用
- Rho JH, Ladd JJ, Li CI, et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer. Gut. 2016. PMID: 27821646. doi:10.1136/gutjnl-2016-312794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。